Novo Nordisk pivots strategy to challenge Eli Lilly in obesity market

Facing stiff competition from Eli Lilly for dominance in the booming obesity drug sector, Novo Nordisk is launching a fundamental cultural overhaul. CEO Mike Doustdar, speaking from the firm’s Copenhagen headquarters, signaled that the Danish pharmaceutical giant must shift toward a more aggressive, customer-centric model to reclaim its market lead.

Editorial·September 15, 2026·reads: 619

Novo Nordisk pivots strategy to challenge Eli Lilly in obesity market

The company’s initiative, dubbed 'The Novo Way,' prioritizes internal competitiveness and deep customer engagement as the primary levers for recovery. This strategic pivot coincides with a broader rebranding effort, including updates to the company name and logo, intended to refresh its corporate identity as the global obesity drug market heads toward an estimated $100 billion annual valuation.

Investors are tracking these developments with heightened scrutiny, noting the company’s early advantage with Wegovy has been eroded by Eli Lilly’s rapid expansion. By embedding new principles into its global workforce, the leadership aims to transition the organization from its established roots into a more nimble participant in the high-stakes weight-loss medication race.